Ritter Pharmaceuticals Inc (NASDAQ:RTTR) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.80 and last traded at $0.82, with a volume of 9527 shares changing hands. The stock had previously closed at $1.07.
A number of equities research analysts recently issued reports on RTTR shares. Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. HC Wainwright set a $15.00 price objective on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 15th. Finally, ValuEngine raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd.
The stock has a market cap of $5.37 million, a P/E ratio of -0.18 and a beta of 1.21.
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.15). On average, sell-side analysts forecast that Ritter Pharmaceuticals Inc will post -2.97 EPS for the current year.
In related news, Director Matthew W. Foehr bought 19,751 shares of the firm’s stock in a transaction on Friday, August 17th. The shares were bought at an average price of $2.04 per share, with a total value of $40,292.04. Following the completion of the transaction, the director now directly owns 54,751 shares of the company’s stock, valued at approximately $111,692.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 21.60% of the company’s stock.
Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
See Also: Exchange-Traded Funds (ETFs)
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.